tbuckley/cabot-search huggingface dataset:
651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Authors: C. Borg, V. Vendrely, A. Saint, T. André, P. Vaflard, E. Samalin-Scalzi, S. Pernot, O. Bouche, J. Desrame, C. de la Fouchardiere, D. Smith, F. Ghiringhelli, A. Vienot, E. Francois, J. Taieb, K. Le Malicot, D. Vernerey, A. Meurisse, S. Kim
Journal: Annals of Oncology (2023)
648P Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Authors: A. Parisi, F. Gelsomino, D. Traisci, F. Barbin, L. Salvatore, F.R. di Pietro, F. Zoratto, A. Lanese, None S. villani, A. Magnarini, A. Spallanzani, N. D'Ostilio, M. Bensi, F. Schietroma, R. Bisonni, M.B.L. Rocchi, R. Giampieri, G. Mentrasti, R. Berardi
Journal: Annals of Oncology (2023)
1163P CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Authors: D. Mallardo, M. Fordellone, A. White, M. Ottaviano, F. Sparano, M. Bailey, B.A. Facchini, S. Ong, P. Maiolino, C. Caracò, S.E. Church, E. Cavalcanti, S. Warren, A. Budillon, A. Cesano, E. Simeone, P. Chiodini, P.A. Ascierto
Journal: Annals of Oncology (2023)
236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Authors: S. Kitagawa, Y. Zenke, K. Yoh, J. Samejima, K. Kunimasa, S. Miyamoto, J. Sakakibara-Konishi, R. Toyozawa, M. Tachihara, S. Niho, K. Nosaki, H. Izumi, T. Sakai, S. Umemura, E. Sugiyama, K. Murai, S. Matsumoto, M. Tsuboi, K. Goto
Journal: Annals of Oncology (2023)
219P Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Authors: E. Jantus Lewintre, A. Rappa, D. Ruano, S. Gallach Garcia, C.J.C. Camps Herrero, L. Lacroix, K. Kashofer, T. van Wezel, M. Barberis
Journal: Annals of Oncology (2023)
215P Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Authors: C.B. Xavier, G. Guardia, J.P. Alves, C.D.H. Lopes, B. Awni, E.F. de Campos, A.A. Camargo, D.L.F. Jardim, P. Galante
Journal: Annals of Oncology (2023)
650P Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Authors: T. Aparicio, J. Henriques, M. Svrcek, A. Zaanan, S. Manfredi, A. Casadei Gardini, D. Tougeron, J-M. Gornet, D. Pezet, None E. terrebonne, G. Piessen, P. Afchain, C. Lecaille, M. Pocard, T. Lecomte, V. Burgio, F. Di Fiore, S. Cascinu, D. Vernerey, P. Laurent Puig
Journal: Annals of Oncology (2023)
1012P First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Authors: A-L. Cheng, C-J. Yen, Q. Cheng, C-C. Lin, P. Huang, D. Li, Y. Li, J. Wang, M. Sun, Q. Wen, S. Gu, X. Du, J. Qian, C. Liu, F. Zhang, C. Dai, G. Li, X. Ding, J. Liu, X-P. Chen
Journal: Annals of Oncology (2023)
218P Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Authors: W.S. Lee, H. Yang, S.J. Lee, S.J. Kong, B. Kang, I. Kim, H. Kim, C. Kim, H. Chon
Journal: Annals of Oncology (2023)
649P The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Authors: M.G. White, B. Helmink, S. Rivero-Hinojosa, N. Bhutiani, V. Aushev, S. Chowdhury, Y. Gu, A. Jurdi, M.C. Liu, K.F. Fournier, J.P.Y-C. Shen
Journal: Annals of Oncology (2023)
546P Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Authors: A. Bertucci, V. Harlay, C. Boucard, G. Petrirena, C. Campello, D. Autran, M. Barrie, O. Chinot, E. Tabouret
Journal: Annals of Oncology (2023)
207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Authors: M.F. Khalil, M. Rothe, P.K. Mangat, E. Garrett-Mayer, K.F. Mileham, E.R. Ahn, H.L. Duvivier, L.C. Farrington, M. Akce, D. Behl, P.J. Gold, V.K. Chiu, N. Vijayvergia, C. Calfa, A. Gaba, F. Meric-Bernstam, S.M. Schuetze, A. Gregory, S. Halabi, R.L. Schilsky
Journal: Annals of Oncology (2023)
211P Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Authors: E. Imyanitov, A. Romanko, E. Preobrazhenskaya, V. Tiurin, A. Venina, R. Mulkidjan, A. Anuskina, A. Togo, A.O. Ivantsov, A.G. Iyevleva
Journal: Annals of Oncology (2023)
210P Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery
Authors: A.R. Filippi, F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi, W. Vos, M. Occhipinti
Journal: Annals of Oncology (2023)
1078TiP Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Authors: K.P. Papadopoulos, J.A. Call, S. Sen, D. Smith, E. van der Horst
Journal: Annals of Oncology (2023)
213P Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Authors: H.E.G. Russnes, H.L. Nilsen, M. Jebens, E. Janssen, R.M. Wold, L.A. Meza-Zepeda, E. Hovig, T. Lien, V. Nygaard, P. Niehusmann, K.M. Ersland, R. Forthun, H.K. Haugland, A.B. Wennerström, T. Lüders, U. Randen, H.Y. Dai, A.V.B. Granlund, A.J. Skjulsvik, R. Hovland
Journal: Annals of Oncology (2023)
1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Authors: S. Sen, A.I. Spira, D. Sommerhalder, F. Meric-Bernstam, V. Subbiah, J.D. Berlin, A. Parikh, M. Cecchini, R.E. Sanborn, P.V. Chablani, G.E. Peoples, T. Schürpf, L.A. Dillon, G.T. Clifton, J.P. Eder, A.W. Tolcher
Journal: Annals of Oncology (2023)
353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01
Authors: S. Patel, J. Thompson, M. Patel, F.J. Daugherty, M. Rimawi
Journal: Annals of Oncology (2023)
2184TiP Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Authors: D.L. Delombaerde, J. De Sutter, L. Croes, D. Vervloet, V. Moerman, N. Van de Veire, A-M. Willems, K. Wouters, M. Peeters, H. Prenen, C. Vulsteke
Journal: Annals of Oncology (2023)
1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Authors: E. Muñoz Couselo, M-Á. Berciano-Guerrero, J.L. Manzano, A. Soria, P. Cerezuela-Fuentes, G. Crespo, M. Antoñanzas, T. Puértolas, A. García Castaño, L. Gutiérrez Sanz, E. Espinosa, P. Ayala de Miguel, M. Majem, R. López Castro, L.A. Fernández-Morales, B. Rivas, J. Medina, A. Berrocal, S. Martín Algarra, I. Márquez-Rodas
Journal: Annals of Oncology (2023)
1166P Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Authors: G. Tarantino, A. Zaremba, T. Vallius, F. Rambow, L. Zimmer, A. Sucker, E. Livingstone, R. Pelletier, S. Makhzami, G. Murphy, C. Lian, P. Sorger, D. Liu, D. Schadendorf
Journal: Annals of Oncology (2023)
1289TiP LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Authors: E. Bria, F. Lococo, L. Boldrini, J. Evangelista, S. Flamini, A. Minucci, E.G.C. Troost, A. Roza, N. Farré, E. Öztürk, A. Urbani, R. Trisolini, A. Giordano, G. Rindi, E. Sala, V. Valentini, S. Boccia, S. Margaritora, G. Scambia, G. Tortora
Journal: Annals of Oncology (2023)
1171P Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Authors: J. Bartolome, C. Nieto-Jimenez, A. López de Sá, C. Diaz-Tejeiro, M. Antonanzas Basa, C. Aguado, A. Manzano Fernández, P. Pérez Segura, A. Ocana Fernandez
Journal: Annals of Oncology (2023)
1181TiP BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Authors: P. Saiag, S. Gourgou, J. Régis, T.M.S. Amaral, U. Leiter-Stoppke, F.C. Bidard, C. Garbe, J.J. Grob, T. Lacornerie, A. Lamrani-Ghaouti, D. Couch, M. Charissoux
Journal: Annals of Oncology (2023)
1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Authors: J-M. Placke, M. Kimmig, K. Griewank, E. Hadaschik, R. Herbst, P. Terheyden, J. Utikal, C. Pfoehler, J. Ulrich, A. Kreuter, P. Mohr, R. Gutzmer, F. Meier, E. Dippel, J. Welzel, J.C. Becker, M. Weichenthal, A. Tasdogan, D. Schadendorf, S. Ugurel-Becker
Journal: Annals of Oncology (2023)
1257P Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Authors: C.H. Burciaga Flores, D.C. Pérez-Ibave, M.D.L. Garza Rodriguez, C.M. Villarreal Garza, O. Vidal-Gutierrez, D. Aguilar
Journal: Annals of Oncology (2023)
1258P Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Authors: A. Ciarmiello, E. Giovannini, F. Tutino, A. Milano, L. Florimonte, E. Bonatto, C.M.R. Bareggi, C. Aschele, M. Castellani, G. Giovacchini
Journal: Annals of Oncology (2023)
1880P Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Authors: C.B. Gonzalez-Alcorta, J.A.M. Moyano, P.A. Lopez Sierra, J.F. Gonzalez Guerrero, A.G. Alcorta Garza, O. Vidal-Gutierre, A. Alcorta-Garza
Journal: Annals of Oncology (2023)
1172P Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Authors: M. Golcic, L. Simetic, D. Herceg, K. Blazicevic, G. Kenđel-Jovanović, I. Dražić, A. Belančić, N. Skočibušić, D. Palčevski, I. Rubinić, V. Vlahović-Palčevski, T. Majnarić, R. Dobrila-Dintinjana, S. Plestina
Journal: Annals of Oncology (2023)
1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
Authors: D. Schadendorf, R. Dummer, A. Ribas, C. Robert, R.J. Sullivan, A. King, A. Polli, A. di Pietro, P.A. Ascierto
Journal: Annals of Oncology (2023)
1169P Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Authors: M.E. Vázquez-Cruz, C. Molina-Aguilar, P. Basurto-Lozada, H. Martinez Said, A. Álvarez Cano, D.Y. Garcia-Ortega, L.A. Tavares-de la Paz, D. Hinojosa-Ugarte, A. Hidalgo Miranda, P. Abrao Possik, I. Ferreira, J.M. Martinez, M.P. Levesque, D. Adams, C.D. Robles-Espinoza
Journal: Annals of Oncology (2023)
1260TiP Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Authors: Y-C. Kim, H-J. Oh, J.Y. Park, S.H. Jang, J. Cho, Y.S. Park, Y.W. Kim, S.Y. Lee, J-K. Yoon, H-P. Kim, S.Y. Kim, T-Y. Kim
Journal: Annals of Oncology (2023)
354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
Authors: E. Hamilton, S. Loibl, N. Niikura, P. Rastogi, K.S. Saini, I. Gioni, T. Klinowska, I. Mayer, M. Stuart, E. Syta, A. Walding, T. Bachelot
Journal: Annals of Oncology (2023)
1177P Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Authors: R. Gutzmer, F. Kiecker, C. Loquai, R. Dummer, A. Hauschild, N. Squittieri, R. Arntz, S. Martelli, J. Dierlamm, C. Robert
Journal: Annals of Oncology (2023)
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE)
Authors: F. Barlesi, O. Mercier, A. Łowczak, S. Mandziuk, J. Kuzdzal, A. Koutras, A. Dasgupta, A.J. Leyco, P. Andre, R. Mager, P.G. Fraenkel, C.L. Paturel, A. Boyer Chammard
Journal: Annals of Oncology (2023)
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Authors: A.M. Czarnecka, P. Teterycz, K. Ostaszewski, P. Blonski, M.K. Zielińska, L. Galus, R. Dziura, N. Kempa-Kamińska, B. Cybulska-Stopa, J. Mackiewicz, M. Ziętek, P. Rutkowski
Journal: Annals of Oncology (2023)
165P Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Authors: M. Gion Cortes, J.J. Garcia Mosquera, J.M. Pérez-García, V. Peg Cámara, J.A. Guerrero, L. López-Montero, M. Mancino, J. Rodríguez Morató, G. Antonarelli, L. Fernández-Murga, L. Serrano García, V. Puglia, A. Llombart Cussac, J. Cortés
Journal: Annals of Oncology (2023)
1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Authors: A.K. Morgans, J.E. Gschwend, N.D. Shore, A. Ross, F. Feng, T. Hope, L. Trandafir, M-A. Le Berre, I. Kuss, H. Joensuu, K. Fizazi
Journal: Annals of Oncology (2023)
150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial
Authors: A. Llombart Cussac, J.M. Pérez-García, L. Pare Brunet, G. Villacampa Javierre, F. Brasó-Maristany, M. Gion Cortes, P. Schmid, M.A. Colleoni, M. Ruiz Borrego, P. Galván, J. Parker, C.M. Perou, P. Villagrasa Gonzalez, J.A. Guerrero, M. Sampayo-Cordero, M. Mancino, A. Prat, J. Cortés
Journal: Annals of Oncology (2023)
149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study
Authors: N. Gomez Serra, F. Brasó-Maristany, B. Fullana Grimalt, R. Ortega, A. Petit, M. Vicente, C. Falo, A. Stradella, M. Bañuls, L. Pare Brunet, M. Marín-Aguilera, A. Fernandez Ortega, A. Vethencourt, D. Cordero, A. Iserte, P. Galván, C.M. Perou, P. Villagrasa Gonzalez, A. Prat, S. Pernas Simon
Journal: Annals of Oncology (2023)
190P Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma
Authors: J.P. Y-C. Shen, A. Yousef, M.M.G. Yousef, M. Zeineddine, S. Chowdhury, M. Knafl, K. Raghav, M.G. White, K. Alfaro-Munoz, B. Helmink, K.F. Fournier, M.J. Overman
Journal: Annals of Oncology (2023)
147P Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies
Authors: P. Saintigny, P. Iriso, M. Afshar, V.K. Attignon, J. Auclair, J. Boulahfa, M. Boussageon, J. Fayette, J-P. Foy, A. Karabajakian, M. Kindermans, M. Lamkhioued, S. Lantuejoul, L. Michon, S. Ortiz-Cuaran, F. Parmentier, M. Pérol, A. Swalduz, T. Turcat
Journal: Annals of Oncology (2023)
159P Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Authors: S. Ni, W. Sheng, W. Su, H. Lu, Q. Yan, J. Xu, C. Hua, Z. Huang, L. Ruan, C. Zhu
Journal: Annals of Oncology (2023)
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
Authors: L. Provenzano, M. Favali, L. Mazzeo, A. Spagnoletti, C. Giani, G. Calareso, M. Ruggirello, F.G. Greco, R. Vigorito, M. Occhipinti, M. Brambilla, S. Manglaviti, C. Proto, G. Lo Russo, F. Trovò, F.G.M. De Braud, M. Ganzinelli, A. Pedrocchi, V. Miskovic, A. Prelaj
Journal: Annals of Oncology (2023)
164P Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Authors: A. Kramer, M.J. Greuter, S. Schraa, G.R. Vink, J. Phallen, V. Velculescu, G. Meijer, D. Van Den Broek, M. Koopman, J.M.L. Roodhart, R. Fijneman, V.P. Retel, V. Coupé
Journal: Annals of Oncology (2023)
143P Is liquid biopsy a good tool for microsatellite instability (MSI) assessment in solid tumors?
Authors: J.E. Rodriguez, K. Beshiri, D. Vasseur, A. Bayle, P. Cascetta, A. Patrikidou, M.V. Sanchez Becerra, M. Tagliamento, M. Aldea, L. Zullo, J.T.M.L. Ribeiro, M. Sakkal, K. Ouali, C. Parisi, A. Hollebecque, O. Cabaret, E. Rouleau, L. Lacroix, A. Italiano, C. Smolenschi
Journal: Annals of Oncology (2023)
185P Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with fusion-positive NSCLC
Authors: J. Patel, R. Ben-Shachar, K. Nadhamuni, M. Carty, R. Pelossof, I. Klein, H. Nimeiri, C. Aggarwal, R.D. Gentzler
Journal: Annals of Oncology (2023)
1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Authors: C. Paller, M. Zahurek, A. Mandl, M. Rudek, E. Heath, C.H. Marshall, M.C. Markowski, A. Lalji, N. Metri, C.J. Hoimes, J. Taksey, J. Durham, W. Kelly, E.S. Antonarakis, M. Eisenberger, M.A. Carducci, S. Denmeade, M. Levine
Journal: Annals of Oncology (2023)
183P Frequency of actionable fusions in 7,735 patients with solid tumors
Authors: K.J. McDonnell, J.R. Hoag, C. Flannery, D. Hall, M.C. Evans, A. Akkunuri, S. Thakkar, J.R. Lobello, G.D. Basu, R.F.L. Baehner, J.D. Bonner, S.S. Lindsey, C. Hong, X. Xia, S. Gray, S.B. Gruber
Journal: Annals of Oncology (2023)
166P Metabolomic prediction of breast cancer treatment toxicities
Authors: M. Piffoux, J. Jacquemin, M. Petera, S. Boyault, A-L. Martin, S. Everhard, F. André, B. Pistilli, M. Fournier, P. Rouanet, A. Dhaini Merimeche, B. Sauterey, M. Campone, C. Tarpin, M.A. Mouret Reynier, O. Rigal, T. Petit, E. Pujos Guillot, Y. Drouet, O. Tredan
Journal: Annals of Oncology (2023)
1844MO Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy
Authors: A.M. Starzer, J.H. Fuerst, E. Tomasich, L. Gottmann, J.M. Berger, M. Korpan, C. Englisch, M. Kleinberger, F. Moik, G. Heller, L. Carlberg, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2023)
1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
Authors: P. Matte, M. Delaye, A. Mc Govern, K. Ouali, F-X. Danlos, C. Henon, V. Goldschmidt, L. Mahjoubi, A. Hollebecque, J-M. Michot, A. Gazzah, R. Bahleda, C. Smolenschi, A. Marabelle, S. Champiat, Y. Loriot, S. Ponce Aix, P. Rouby, C. Lemogne, C. Baldini
Journal: Annals of Oncology (2023)
191P Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment
Authors: K.R. Bisson, A. Beharry, M.D. Carter, S. Dudani, J.G. Garratt, J.M. Loree, S. Snow, S. Yip, J.R. Won, B.S. Sheffield
Journal: Annals of Oncology (2023)
181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative
Authors: P.G. Aftimos, K. Punie, L. Decoster, C. Van Marcke de Lummen, A. Hebrant, G. Raicevic, E. Van Valckenborgh, B. Maes, J. Maetens, J.J. Collignon, T.F.A. van den Mooter, J. Fried-Vermeij, W. Demey, S. Tejpar, M. Peeters, J-L. Canon, W. Lybaert, J. Mebis, S. Rottey, J. De Grève
Journal: Annals of Oncology (2023)
1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial
Authors: A.A. Azad, Y. Wang, M. Hadigol, J. Hoffman, N. Agarwal, N. Matsubara, V.R. Lincha, F. Zohren, L. DeAnnuntis, D. Wang
Journal: Annals of Oncology (2023)
1830P CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Authors: K. Li, J. Wu, S. Ye, None Y. liu, H. Huang, None F. fan, None Y. lai, S. Zhuang, L. Zhou, R. Huang, Y. Teng, X. Chai, J. Zhang, Y. Shi, H. Huang
Journal: Annals of Oncology (2023)
176P Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
Authors: M. Ligero, O.S.M. El Nahhas, O. Prior Palomares, V. Navarro, I. Sansano, G. Serna, S. Mauchanski, R.D.A. Toledo, R. Dienstmann, S. Ramon y Cajal, E. Garralda, P.G. Nuciforo, J.N. Kather, R. Perez Lopez
Journal: Annals of Oncology (2023)
173P Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Authors: J. Khandare, G. Aland, M. Garbhe, S. Gosavi, G. Khutale, M. Patil, V. Tulpule, P. Lokhande, A. Ashturkar, V. Jadhav, A. Vasudevan, S. Jayant, A. Bharde
Journal: Annals of Oncology (2023)
153P Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis
Authors: P. Torres-Mozas, F. Galvez Montosa, N. Luque Caro, F.J.G. Verdejo, A.L.O. Ortega Granados, J. Requena Aguilar, J.Z. Benoit Perejón, R. Garcia Munoz, G.P. Vinueza Hidalgo, I. Fernández Ros, P. Sanchez-Rovira
Journal: Annals of Oncology (2023)
1832P Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Authors: J. Freire, B. Caramelo, I. Duran Martinez, S. del Carmen, A. Azueta, P. García-Berbel, P.D. Diaz, D. Cacho Lavin, M. Orellana, M. Lencina, C. Mordillo, J. Gómez
Journal: Annals of Oncology (2023)
1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Authors: L.G. Horvath, C. Kench, R. Mellor, H-M. Lin, B. Mak, T. Scheinberg, K. Mahon, L. Graham, A.A. Azad, A.M. Joshua, M.R. Stockler, G.M. Marx, K. Briscoe, K. Samaras
Journal: Annals of Oncology (2023)
167P A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Authors: T. Yujing, Y. Guan, Y. Chen, D. Ji, J. Wang, F. Ma, Y. Luo, P. Zhang, X. You, W. Xi, Y. Song, B. Xu, Y. Fan
Journal: Annals of Oncology (2023)
148P DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Authors: V. Makker, J-Y. Lee, D-Y. Oh, A. Oaknin, S.D. Puvvada, F. Cecchi, R. Mcewen, F. Michelini, F. Meric-Bernstam
Journal: Annals of Oncology (2023)
156P The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer
Authors: R.S. Pedersen, J. Thorlacius-Ussing, N.I. Nissen, A. Johansen, I. Chen, C. Jensen, C. Hansen, M. Karsdal, J.S. Johansen, N. Willumsen
Journal: Annals of Oncology (2023)